BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 31424273)

  • 1. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
    Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
    BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
    Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
    Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
    Bellizzi AM
    Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
    Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives.
    Hijioka S; Morizane C; Ikeda M; Ishii H; Okusaka T; Furuse J
    Jpn J Clin Oncol; 2021 Aug; 51(8):1185-1196. PubMed ID: 34038547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Diarrhea in Patients With Carcinoid Syndrome.
    Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
    Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.
    Chen YY; Guo WJ; Shi YF; Su F; Yu FH; Chen RA; Wang C; Liu JX; Luo J; Tan HY
    BMC Gastroenterol; 2023 Dec; 23(1):440. PubMed ID: 38097952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
    Giri S; Sahoo J
    World J Gastroenterol; 2024 Mar; 30(12):1670-1675. PubMed ID: 38617746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort.
    Panzuto F; Andrini E; Lamberti G; Pusceddu S; Rinzivillo M; Gelsomino F; Raimondi A; Bongiovanni A; Davì MV; Cives M; Brizzi MP; Persano I; Zatelli MC; Puliafito I; Tafuto S; Campana D
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610840
    [No Abstract]   [Full Text] [Related]  

  • 10. A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.
    De Divitiis C; von Arx C; Carbone R; Tatangelo F; Di Girolamo E; Romano GM; Ottaiano A; de Lutio di Castelguidone E; Iaffaioli RV; Tafuto S
    Onco Targets Ther; 2015; 8():669-75. PubMed ID: 25878507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory carcinoid syndrome: a review of treatment options.
    Riechelmann RP; Pereira AA; Rego JF; Costa FP
    Ther Adv Med Oncol; 2017 Feb; 9(2):127-137. PubMed ID: 28203303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors.
    Cuyle PJ; Prenen H
    Ann Gastroenterol; 2018; 31(2):140-150. PubMed ID: 29507461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-cirrhotic hyperammonaemic encephalopathy secondary to metastatic pancreatic neuroendocrine tumour treated with peptide receptor radio nucleotide therapy and transarterial chemoembolisation.
    Holmes Z; Beasley H; Naidoo M; Michael M
    BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38171636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies.
    Lee L; Ramos-Alvarez I; Jensen RT
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267558
    [No Abstract]   [Full Text] [Related]  

  • 15. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
    Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
    Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
    Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
    Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
    Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
    Perez K; Chan J
    Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.